Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...

A multiple sclerosis diagnosis used to mean a future of disability. But now, a revolution in medications allows MS patients to pursue their dreams.

Findings showed fenebrutinib significantly reduced relapses vs teriflunomide in RMS and was noninferior to ocrelizumab in slowing disability progression in PPMS. Topline data were announced from two ...